We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Peptide from Umbilical Cord Blood Shuts Down a Neutrophil Inflammatory Factor

By LabMedica International staff writers
Posted on 19 Sep 2016
Researchers have isolated a peptide in umbilical cord blood that blocks the formation of neutrophil extracellular traps (NETs) and reduces inflammation and risk of developing sepsis.

NETs are molecular lattices of decondensed chromatin embedded with histones, granule enzymes, and antimicrobial peptides that are extruded by immune system neutrophil granulocytes, (polymorphonuclear leukocytes or PMNs) to capture and contain bacteria, viruses, and other pathogens. More...
Experimental evidence has indicated that NETs also cause inflammatory vascular and tissue damage, suggesting that identifying pathways that inhibit NET formation may have therapeutic implications.

After examining various potential sites for the presence of a NET inhibitor, investigators at University of Utah Health Care (Salt Lake City, USA) discovered a peptide in umbilical cord blood that inhibited NET formation in vitro and in vivo and that appeared to be an endogenous regulator of NET generation.

They reported in the September 6, 2016, online edition of The Journal of Clinical Investigation that in addition to this neonatal NET-inhibitory factor (nNIF), they had also identified additional nNIF-related peptides (NRPs) that inhibited NET formation. These nNIFs and NRPs blocked NET formation induced by pathogens, microbial toxins, and pharmacologic agonists in vitro and in mouse models of infection and systemic inflammation, and they improved mortality in mouse models of systemic inflammation.

"We found something we were not expecting, and it has taken us to new strategies for therapy that did not exist before," said senior author Dr. Guy Zimmerman, professor of internal medicine at University of Utah Health Care.

Related Links:
University of Utah Health Care


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.